Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4555931 | 0.83 | ALDH1A1 (0.42) | MAPTMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL4555285 | 0.81 | PLD1 (0.49) | LMNAMAPTMEN1KMT2AHTT | |
| SCHEMBL4555805 | 0.76 | MAPT (0.48) | LMNAMAPTKMT2AGAAHTT | |
| SCHEMBL8804737 | 0.75 | LIPA (0.42) | LMNAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL10498542 | 0.74 | LMNA (0.70) | LMNAMAPTMEN1KMT2AGAA | |
| SCHEMBL6663539 | 0.74 | — | — | |
| SCHEMBL8806823 | 0.74 | LIPA (0.45) | LMNAMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL8805846 | 0.72 | POLB (0.39) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2383830 | 0.71 | PDE10A (0.41) | MAPTALDH1A1KDM4E | |
| SCHEMBL2207978 | 0.71 | ALDH1A1 (0.63) | LMNAMAPTMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103497148-A | Hydroxylamine compounds and methods of their use | OTHERA HOLDING INC | 2014-01-08 | — | — | CN | disclosed |
| EP-2620429-A1 | Hydroxylamine compounds and methods of their use | Colby Pharmaceutical Company (US) | 2013-07-31 | — | — | EP | disclosed |
| CN-101687786-B | Hydroxylamine compounds and methods of use thereof | OTHERA HOLDING INC | 2013-05-22 | — | — | CN | disclosed |
| CN-101687786-A | Hydroxylamine compounds and methods of use thereof | OTHERA HOLDING INC | 2010-03-31 | — | — | CN | disclosed |
| EP-2125716-A2 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | Othera Holding, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-2120942-A2 | DRUG RESISTANCE REVERSAL IN NEOPLASTIC DISEASE | Othera Holding, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080280890-A1 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | COLBY PHARMACEUTICAL COMPANY | 2008-11-13 | — | — | US | disclosed |
| WO-2008103613-A2 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | OTHERA HOLDING, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20080200405-A1 | Drug Resistance Reversal In Neoplastic Disease | COLBY PHARMACEUTICAL COMPANY | 2008-08-21 | — | — | US | disclosed |
| WO-2008101195-A2 | DRUG RESISTANCE REVERSAL IN NEOPLASTIC DISEASE | OTHERA HOLDING, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280890-A1 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | HDGF, HMOX1, HMOX2 | LMNA 1875/4885MAPT 2334/4885MEN1 2273/4885 |
| US-20080200405-A1 | Drug Resistance Reversal In Neoplastic Disease | VHL, ABCC1, SLC11A2 | LMNA 1465/4885MAPT 2753/4885MEN1 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.